Krytantek Oteno PF® 或 Eliptic Otenno PF® Plus Gaap Otenno PF® 治疗 POAG 或高眼压症疗效的比较研究。 (PRO-122)

实验性的：手臂 1；多佐胺-噻吗洛尔-溴莫尼定和拉坦前列素； Krytantek Oteno PF® 和 Gaap Oteno PF®

在研究期间（总暴露时间：90 天）每 24 小时 21:30（± 15 分钟）使用 Gaap Oteno®（拉坦前列素 0.005%；不含防腐剂）滴眼液。 开始 Gaap Oteno® 滴注一个月后，将在每 12 小时 9:00 和 21:00 (± 10分钟）（总曝光时间：60 天）。

药品：多佐胺-噻吗洛尔-溴莫尼定和拉坦前列素

每 24 小时使用 Gaap Otenno PF®，持续 30 天，同时伴随使用 Krytantek Oteno PF®，每 12 小时使用一次，持续 60 天。 总干预时间：90天。

其他名称：

• PRO-122
• Krytantek Oteno PF®
• Gaap Oteno PF®

实验性的：手臂 2；多佐胺-噻吗洛尔和拉坦前列素； Eliptic Oteno PF® 和 Gaap Oteno PF®

在研究期间（总暴露时间：90 天）每 24 小时 21:30（± 15 分钟）使用 Gaap Oteno®（拉坦前列素 0.005%；不含防腐剂）滴眼液。 开始 Gaap Oteno® 滴注一个月后，将每 12 小时在 9:00 和 21:00 时（± 10 分钟）添加 Eliptic Oteno®（多佐胺 2% 和噻吗洛尔 0.5%；不含防腐剂）滴眼液（总暴露：60 天）。

药品：多佐胺-噻吗洛尔和拉坦前列素

每 24 小时使用 Gaap Otenno PF®，持续 30 天，同时伴随使用 Eliptic Oteno PF®，每 12 小时使用一次，持续 60 天。 总干预时间：90天。

其他名称：

• Gaap Oteno PF®
• Eliptic Oteno PF®

Change in Intraocular Pressure (IOP)

Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP is evaluated at 9:00 and at 11:00 hrs. (± 30 minutes). Both measurements and their average will be registered. Normal values are considered between 10 and 21 mmHg. Assessed at the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, reported only for first follow-up visit, second follow-up visit and final visit.

眼部舒适指数的变化

眼部舒适度指数 (OCI) 问卷将用于通过干眼症状的发生率和严重程度以 0 到 100 的等级评估耐受性。 更高的分数意味着更差的结果。

Best Corrected Visual Acuity (BCVA)

Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

BCVA was compared between groups and between visits. Assessed at the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, reported only for first follow-up visit, second follow-up visit and final visit.

Optic Nerve Cup/Disc Ratio (Baseline Vist vs Final Visit)

Both clinical and imaging evaluation will be performed. For clinical evaluation, after the application of a topical ophthalmic mydriatic (tropicamide 0.8% / phenylephrine 5%), indirect ophthalmoscopy will be performed through the aid of a fundus lens in a slit lamp. For imaging, optic coherence tomography (OCT) will be used. Assessed and reported only for the basal visit and final visit.

Mean Value in Nerve Fibers and Ganglion Cell Thickness

Spectral domain OCT is a non invasive tool that will be used to evaluate quantitatively the thickness of retinal nerve fibers and ganglion cell layers. The mean observed in the nerve fibers and ganglion cell thickness was calculated. This was assessed and reported only for the basal and final visit.

Optic Nerve Image

Through a fundus camera a photograph will be taken to obtain a faithful record of any possible changes to the optic nerve head characteristics. Its classification as "small", "medium" or "large" relied on the expertise of the PI, the percentage of cases in each classification ("small", "medium" or "large") was reported. Assessed and reported only for the basal visit and final visit.

Central Corneal Thickness (CCT)

Measured through ultrasonic pachymetry, three assessments will be performed, these and its average will be recorded. Assessed and reported for the basal visit and final visit.

Change in Visual Fields

Visual fields will be assessed using standard automated SITA (Swedish Interactive Thresholding Algorithm) white-on-white perimetry performed with a Humphrey perimeter. To be considered reliable, fixation losses, false positives, and false negatives must be less than 20%.

The mean deviation (MD) was recorded, which is a measure of overall field loss. The standard deviation of the pattern was also recorded, which is a measure of focal loss or variability within the field. A higher score is a worse result.

The theoretical value or reported range for the average deviation is from +2.00 to -35 dB.

Change in Ocular Surface Integrity (Chemosis)

By means of a slit lamp chemosis will be evaluated. Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. The number and percentage of participants in each category was reported.

Number of Adverse Events

Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution.

Change in Ocular Surface Integrity (Conjunctival Hyperemia)

By means of a slit lamp conjunctival hyperemia will be evaluated. Conjunctival hyperemia will be graded according to Efron's scale (5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4)).

Percentage of Cases Who Reached a Specific IOP Decrease in mmHg

Percentage of cases who reached a reduction in IOP within the following ranges: ≤12, ≤13, ≤14, ≤15, or ≤18 mmHg. Each range is a classification and the percentage is calculated with the counts of cases in each classification. PIO was assessed in the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, and was reported for the first follow-up visit, second follow-up visit, and final visit.

The initial objective of the study was to report the percentage of patients who achieved a specific reduction in intraocular pressure (IOP). However, because the study ended early, the number of participants was limited, and both eyes per patient were included, we chose to present the full dataset in order to provide a more comprehensive report.

Percentage of Cases Who Reached a Specific IOP Decrease in Percentage

Cases who demonstrated decrease in IOP within the following percentage ranges: ≥ 20%, ≥ 25%, ≥ 30%, y ≥ 35%. Each range is a classification and the percentage is calculated with the counts of cases in each classification. PIO was assessed in the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, and was reported for the first follow-up visit, second follow-up visit, and final visit.